

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUTCHMED (China) Limited**

**和黃醫藥（中國）有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 13)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on November 29, 2024.

By Order of the Board

**Edith Shih**

*Non-executive Director and Company Secretary*

Hong Kong, November 29, 2024

As at the date of this announcement, the Directors of the Company are:

**Chairman and Non-executive Director:**

Dr Dan ELDAR

**Executive Directors:**

Dr Weiguo SU

*(Chief Executive Officer and  
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

*(Chief Financial Officer)*

**Non-executive Directors:**

Ms Edith SHIH

Ms Ling YANG

**Independent Non-executive Directors:**

Mr Paul Rutherford CARTER

*(Senior Independent Director)*

Dr Renu BHATIA

Dr Chaohong HU

Mr Graeme Allan JACK

Professor MOK Shu Kam, Tony

## Total Voting Rights

**Hong Kong, Shanghai & Florham Park, NJ — Friday, November 29, 2024:** HUTCHMED (China) Limited (“[HUTCHMED](#)”) (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at November 29, 2024, the issued share capital of HUTCHMED consisted of 871,601,095 ordinary shares of US\$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 871,601,095 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 871,601,095 ordinary shares would be equivalent to 871,601,095 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,320,219 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

### About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](#).

### CONTACTS

**Investor Enquiries** +852 2121 8200 / [ir@hutch-med.com](mailto:ir@hutch-med.com)

#### Media Enquiries

Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / [HUTCHMED@fticonsulting.com](mailto:HUTCHMED@fticonsulting.com)

Zhou Yi, Brunswick +852 9783 6894 (Mobile) / [HUTCHMED@brunswickgroup.com](mailto:HUTCHMED@brunswickgroup.com)

#### Nominated Advisor

Atholl Tweedie / Freddy Crossley / +44 (20) 7886 2500  
Rupert Dearden, Panmure Liberum